# Mozobil for Autologous Hematopoietic Stem Cell Transplantation

> **NCT07188090** · PHASE2 · RECRUITING · sponsor: **Thomas Jefferson University** · enrollment: 100 (estimated)

## Conditions studied

- Multiple Myeloma
- Hodgkin Lymphoma
- Non-hodgkin Lymphoma

## Interventions

- **DRUG:** Plerixafor
- **DRUG:** Gcsf

## Key facts

- **NCT ID:** NCT07188090
- **Lead sponsor:** Thomas Jefferson University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-16
- **Primary completion:** 2027-12
- **Final completion:** 2028-06
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2025-11-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07188090

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07188090, "Mozobil for Autologous Hematopoietic Stem Cell Transplantation". Retrieved via AI Analytics 2026-07-23 from https://api.ai-analytics.org/clinical/NCT07188090. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*